Interleukin-2 in metastatic melanoma: establishing a role

Editorial

M B Atkins. Cancer J Sci Am. 1997 Dec.

. 1997 Dec:3 Suppl 1:S7-8.

No abstract available

Comment on

Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Legha SS, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S9-15. Cancer J Sci Am. 1997. PMID: 9457387 Clinical Trial.
Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma.
Antoine EC, Benhammouda A, Bernard A, Youssef A, Mortier N, Gozy M, Nizri D, Auclerc G, Rocher MA, Soubrane CL, Weil M, Khayat D. Antoine EC, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S16-21. Cancer J Sci Am. 1997. PMID: 9457388 Clinical Trial.
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U, Stoter G, Punt CJ, Scheibenbogen C, Lejeune F, Eggermont AM. Keilholz U, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S22-8. Cancer J Sci Am. 1997. PMID: 9457389 Review.
Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A. Thompson JA, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S29-34. Cancer J Sci Am. 1997. PMID: 9457390 Clinical Trial.